HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KALA
KALA BIO, Inc.
There isn't enough reported data to score KALA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KALA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KALA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KALA PE Valuation
KALA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KALA Forward outlook
There aren't enough analyst estimates for KALA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
KALA has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus KALA down 140%.
KALA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$204.63 | +$302.87 |
| Q3 2025 | -$252.50 | +$341.50 |
| Q2 2025 | -$295.50 | +$372.50 |
| Q1 2025 | -$368.00 | +$360.00 |
| Q4 2024 | -$507.50 | +$360.00 |
| Q3 2022 | -$2,862.50 | +$2,237.50 |
| Q2 2022 | -$4,900.00 | +$375.00 |
| Q1 2022 | -$5,375.00 | -$475.00 |
KALA is still losing money, but far less than before: $204.63 per share over the past year, against $7,225.00 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for KALA.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KALA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $420K | -86% |
| Q2 2022 | $2.1M | -31% |
| Q1 2022 | $1.4M | -58% |
| Q4 2021 | $1.9M | -17% |
| Q3 2021 | $3.1M | +38% |
| Q2 2021 | $3.1M | +266% |
| Q1 2021 | $3.3M | +205% |
| Q4 2020 | $2.2M | +90% |
KALA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -3469% | -2619 points |
| Q2 2022 | -1237% | -285 points |
| Q1 2022 | -2253% | -1386 points |
| Q4 2021 | -2522% | -1227 points |
| Q3 2021 | -850% | +314 points |
| Q2 2021 | -952% | +1603 points |
| Q1 2021 | -867% | +1012 points |
| Q4 2020 | -1295% | +417 points |
KALA's operating margin was −3469% last quarter, down 2619 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KALA on cash generation, producing positive trailing cash flow while its opponent burns cash.
KALA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.5M | +$15M |
| Q1 2026 | -$2.9M | +$5.9M |
| Q4 2025 | -$4.6M | +$42K |
| Q3 2025 | -$10.9M | -$6.2M |
| Q2 2025 | -$16.6M | -$7.3M |
| Q1 2025 | -$8.8M | +$2M |
| Q4 2024 | -$4.6M | +$3.1M |
| Q3 2024 | -$4.7M | -$1.8M |
KALA has burned cash in almost every quarter: −$20M over the past year, against −$35M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KALA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -54% | -88.8K shares |
| 1 year | -42% | -52.8K shares |
| 3 years | +145% | +44K shares |
| 5 years | +231% | +51.7K shares |
| Available history | +443% | +60.5K shares |
KALA has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KALA Net Leverage
KALA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KALA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 4.7 | Oversold |
KALA's weekly RSI is 33 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KALA PE vs Healthcare Sector
KALA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KALA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.25 | 36% below |
| 20 week MA | $0.59 | 73% below |
| 50 week MA | $9.99 | 98% below |
| 100 week MA | $160.4 | 100% below |
| 200 week MA | $321.9 | 100% below |
KALA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over KALA on returns for 2026, with the stronger performance.
KALA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9,325.0 | $19,150.0 | +105% |
| 2021 | $19,150.0 | $3,400.0 | -82% |
| 2022 | $3,400.0 | $194.0 | -94% |
| 2023 | $194.0 | $350.0 | +80% |
| 2024 | $350.0 | $349.0 | -0.3% |
| 2025 | $349.0 | $32.5 | -91% |
| 2026 YTD | $32.5 | $0.16 | -100% |
KALA's yearly returns have swung widely, from +105% in 2020 to −94% in 2022. It's down 100% so far in 2026.